Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion, increased product competition and restrictive reimbursement environments will cause the asthma drug market to decline from $13.4 billion in 2009 to less than $12.9 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Asthma reveal that the principal factor that will erode overall sales of asthma therapies will be the loss of brand exclusivity of Merck/Kyorin's Singulair (montelukast), following the entry of generic versions of the drug, beginning in 2012 in the U.S. and Europe. Owing to generic erosion and increasing competition, other key brands that will experience declining sales include GlaxoSmithKline's Advair/Seretide/Adoair (salmeterol/fluticasone propionate) and AstraZeneca/Astellas's Symbicort (formoterol/budesonide).

The Pharmacor 2010 findings reveal that, with no new blockbuster drug class in sight, the asthma drug market will be defined over the next decade by product life-cycle management and incremental product development such as new formulations, new combinations and new delivery devices. Emerging agents will also face the challenge of differentiating themselves from available therapies.

"Given the increasingly restrictive reimbursement environments across the major pharmaceutical markets, emerging agents that offer improved dosing convenience will effectively capture market share only if they are priced competitively," said Decision Resources Analyst Martin Quinn. "Other key emerging players will also need to rely on competitive pricing, in addition to incremental gains in safety or improved efficacy, to differentiate themselves from competitors."

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or

  registered trademarks of their respective holders.       Decision Resources, Inc.   Christopher Comfort   781-296-2597 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, Inc., +1-781-296-2597,

The Launch and Uptake of Nine Emerging Therapies Will Drive the Prostate Cancer Drug Market to More Than Double to $8.4 Billion in 2019

View Now